• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Entero's Grid AI Prepares for Major U.S. Expansion with New Leadership Appointments to Accelerate AI Infrastructure Strategy

    11/13/25 8:35:00 AM ET
    $ENTO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ENTO alert in real time by email

    Timed with a sharp acceleration in AI-data-center expansion, with more than $60B in new projects announced in the last 90 days.

    BOCA RATON, FL / ACCESS Newswire / November 13, 2025 / Entero Therapeutics, Inc. (NASDAQ:ENTO) ("Entero" or the "Company") today announced that its wholly owned subsidiary, Grid AI, is finalizing the establishment of a U.S.-based leadership team composed of highly accomplished executives from the energy, power, and technology sectors. This marks a significant step in Grid AI's expansion into the rapidly growing U.S. market for AI-ready digital infrastructure and orchestration technology.

    Entero expects to announce the appointment of a U.S.-based Chief Executive Officer and an Executive Chairman for Grid AI in the near term. The incoming executive team brings deep public-markets experience, including having grown and led a global, publicly traded company in the demand-response and energy-flexibility sector. Their leadership track record is directly aligned with Grid AI's strategy to integrate AI orchestration, energy optimization, and digital infrastructure controls across major hyperscale and enterprise AI deployments.

    Grid AI's leadership expansion comes at a pivotal moment for the global compute industry. This week, AMD CEO Dr. Lisa Su projected that the data-center market will reach $1 trillion globally by 2030. Supporting that growth is expected to require more than 2,000 new data centers worldwide, each demanding intelligent control systems, AI-driven power orchestration, and real-time market optimization-capabilities core to the Grid AI platform.

    With the addition of this experienced U.S.-based leadership team, Grid AI is positioning itself to build the operational depth, deployment capability, and public-markets governance rigor required for the next phase of hyperscale AI infrastructure development.

    "More than $50 million has been invested since 2019 to build, test, and commercialize this revolutionary autonomous platform," said Jason Sawyer, CEO of Entero. "Establishing a dedicated U.S. leadership team now gives us the product-market fit and execution muscle to accelerate our integration into the domestic AI infrastructure landscape and support large-scale AI-driven SaaS deployments."

    Grid AI will provide additional updates on leadership appointments and U.S. expansion initiatives in the coming weeks.

    Grid AI's U.S. expansion plans are aligned with Entero's broader objective to capture value across the rapidly evolving intersection of artificial intelligence, energy systems, and digital infrastructure.

    Investor & Media Contacts:

    Entero Investor Relations:
    [email protected]

    SOURCE: Entero Therapeutics, Inc.



    View the original press release on ACCESS Newswire

    Get the next $ENTO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENTO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ENTO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Entero Therapeutics Appoints Richard Paolone as CEO

    BOCA RATON, Fla., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (NASDAQ:ENTO) ("Entero" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that the board of directors has appointed Mr. Richard Paolone as the interim CEO of the Company. Richard Paolone is a Toronto-based securities lawyer with extensive experience in corporate finance, securities law, and mergers and acquisitions. Mr. Paolone plays a key role in advising on a range of strategic business initiatives and has represented numerous companies in both private and public offerings of debt

    2/14/25 4:00:00 PM ET
    $ENTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members

    BOCA RATON, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (NASDAQ:ENTO) ("Entero" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that it has secured a $2 million revolving loan agreement and subsequently appointed three new members to its Board of Directors. As a condition for the loan, Entero replaced three of five members of its Board of Directors with three new directors designated by the lender. These appointments follow the resignations of James Sapirstein, Alastair Riddell and Timothy Ramdeen from the Board. Richard Paolone, a Tor

    2/7/25 3:22:22 PM ET
    $ENTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum

    BOCA RATON, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ:ENTO), ("Entero Therapeutics" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and CEO of Entero Therapeutics, will moderate the "CEO Insights: Lessons Learned & Strategies for Driving Innovation," CEO Forum which will be held on Tuesday, November 19, 2024 at the Swan Hotel in Orlando, Florida. The session will feature several CEOs as panelists and will be open to senior executives from the Florida Life Science ecosystem. Details of the even

    11/14/24 8:00:00 AM ET
    $ENTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTO
    SEC Filings

    View All

    Entero Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - GridAI Technologies Corp. (0001604191) (Filer)

    12/4/25 5:21:38 PM ET
    $ENTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Entero Therapeutics Inc.

    10-Q - Entero Therapeutics, Inc. (0001604191) (Filer)

    11/19/25 5:13:53 PM ET
    $ENTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-Q filed by Entero Therapeutics Inc.

    NT 10-Q - Entero Therapeutics, Inc. (0001604191) (Filer)

    11/17/25 4:01:28 PM ET
    $ENTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Pursglove Geordan Garrett

    3 - Entero Therapeutics, Inc. (0001604191) (Issuer)

    8/18/25 6:58:09 PM ET
    $ENTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Sawyer Jason David

    3 - Entero Therapeutics, Inc. (0001604191) (Issuer)

    8/18/25 6:56:34 PM ET
    $ENTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Uppal Manpreet

    3 - Entero Therapeutics, Inc. (0001604191) (Issuer)

    2/13/25 5:02:13 PM ET
    $ENTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTO
    Leadership Updates

    Live Leadership Updates

    View All

    Entero Therapeutics Appoints Richard Paolone as CEO

    BOCA RATON, Fla., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (NASDAQ:ENTO) ("Entero" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that the board of directors has appointed Mr. Richard Paolone as the interim CEO of the Company. Richard Paolone is a Toronto-based securities lawyer with extensive experience in corporate finance, securities law, and mergers and acquisitions. Mr. Paolone plays a key role in advising on a range of strategic business initiatives and has represented numerous companies in both private and public offerings of debt

    2/14/25 4:00:00 PM ET
    $ENTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

    Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

    10/8/24 5:00:00 AM ET
    $ENTO
    $OCS
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care